Phase III Study Comparing Anlotinib Plus Icotinib to Icotinib in Patients With Untreated Non-squmous NSCLC Harboring EGFR Concomitant Mutations
Latest Information Update: 03 May 2023
At a glance
- Drugs Catequentinib (Primary) ; Icotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms SAINT
- 18 Mar 2021 New trial record